ERBB2 and breast carcinoma: However, other targeted therapies that have proven effective for patients with ERα-positive or HER2-overexpressing subtypes of breast cancer are not available for TNBC due to the lack of ERα and PR expression and HER2 amplification, thus leaving most women with TNBCs without targeted treatment options.